Updated 02/10/2017

Ophthotech Corp. A PHASE 3 RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS ADMINISTRATION OF FOVISTATM (ANTI PDGF-B PEGYLATED APTAMER) ADMINISTERED IN COMBINATION WITH EITHER AVASTIN® OR EYLEA® COMPARED TO AVASTIN® OR EYLEA® MONOTHERAPY IN SUBJECTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 2015- Present.

Allergan. SAFETY AND EFFICACY OF BRIMONIDINE POSTERIOR SEGMENT DRUG DELIVERY SYSTEM IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. 2015- Present.

Alcon. A TWO-YEAR, RANDOMIZED, DOUNLE-MASKED, MULTICENTER, THREE ARM, STUDY COMPARING THE EFFICACY AND SAFETY OF RTH258 VERSUS AFLIBERCEPT IN SUBJECT WITH NEOVASUCULAR AGE-RELATED MACULAR DEGENERATION. 2015- Present.

Roche. A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. 2015- Present.

Roche. A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. 2016.

Regeneron. A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED DOSES OF INTRAVITREAL REGN910-3 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 2016.

Roche. A MULTIPLE-CENTER, MULTIPLE-DOSE, RANDOMIZED, ACTIVE COMPARATOR−CONTROLLED, DOUBLE-MASKED, PARALLEL GROUP, 28-WEEK STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO6867461 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH DIABETIC MACULAR EDEMA. 2016.

Roche. A MULTIPLE-CENTER, MULTIPLE-DOSE AND REGIMEN, RANDOMIZED, ACTIVE COMPARATOR CONTROLLED, DOUBLE-MASKED, PARALLEL GROUP, 36 WEEK STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO6867461 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. 2016.

Regeneron/Panorama. A Phase 3, Doubled-Masked, Randomized Study of the Efficacy and Safety of intravitreal Afilbercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy

Roche/Stairway. A Phase II, Randomized,Active Comparator-Controlled, Subject and Outcome-Assessor Masked, Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

VisionCare’s Implantable Miniature Telescope. A Prospective, Multicenter Clinical Trial of the Implantable Miniature Telescope in Pseudophakic Eyes with Central Vision Impairment Associate with End-Stage Macular Degeneration.

Astellas Institute for Regenerative Medicine. A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration. (Human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells [ASP7317})